Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
用户XI0e7myaIGWw
6小时前
11
10
待确认
帖子自动结束时间: 2025-10-15 14:09:36
1. 请及时下载文件确认是否正确, 系统将在 2025-10-17 14:09:52 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S0140-6736(25)01073-6
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673625010736
其他信息:
出版社: Elsevier BV
作者: Mazen Noureddin; Juan P Frias; Guy W Neff; K Jean Lucas; Cynthia Behling; Pierre Bedossa; Julie Dubourg; Doreen Chan; Mark Burch; Erica Fong; Brittany de Temple; Matt Minerva; Kim Barrett; Reshma Shringarpure; Erik J Tillman; Timothy Rolph; Andrew Cheng; Kitty Yale
